NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 studies, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.
![NewAmsterdam Pharma logo](/files/LOGO/1936258-NAMS.png)
Company profile
Ticker
NAMS
Exchange
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
NewAmsterdam Pharma Co B.V.
SEC CIK
NAMS stock data
Latest filings (excl ownership)
8-K
NewAmsterdam Pharma Announces Issuance of Composition of Matter Patent for Obicetrapib by the United
11 Jun 24
8-K
Submission of Matters to a Vote of Security Holders
7 Jun 24
ARS
2023 FY
Annual report to shareholders
9 May 24
DEF 14A
Definitive proxy
9 May 24
8-K
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
9 May 24
10-Q
2024 Q1
Quarterly report
8 May 24
PRE 14A
Preliminary proxy
29 Apr 24
424B3
Prospectus supplement
19 Apr 24
EFFECT
Notice of effectiveness
18 Apr 24
POS AM
Prospectus update (post-effective amendment)
12 Apr 24
Latest ownership filings
3
WILLIAM A JONES JR
3 May 24
4
Juliette Berangere Audet
2 Apr 24
4
James N Topper
28 Mar 24
4
Johannes Jacob Pieter Kastelein
27 Mar 24
144
Notice of proposed sale of securities
26 Mar 24
SC 13D/A
BCLS II Investco, LP
1 Mar 24
4
LOUIS G LANGE
21 Feb 24
SC 13D/A
Frazier Life Sciences X, L.P.
21 Feb 24
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 24
SC 13G/A
VIKING GLOBAL INVESTORS LP
14 Feb 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Dec 22 | Nov 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Nov 22 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Institutional ownership, Q1 2024
13F holders | Current |
---|---|
Total holders | 80 |
Opened positions | 72 |
Closed positions | 2 |
Increased positions | 1 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 1.70 tn |
Total shares | 109.48 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Frazier Life Sciences Management | 12.23 mm | $289.17 bn |
Capital Fund IV Cooperatief U.A. Forbion | 11.83 mm | $163.87 mm |
FCPM Iii Services B.V. | 11.83 mm | $279.81 bn |
Bain Capital Life Sciences Investors | 10.47 mm | $247.71 bn |
Viking Global Investors | 8.02 mm | $189.78 bn |
Ra Capital Management | 7.86 mm | $185.98 bn |
Frazier Life Sciences X | 7.30 mm | $151.28 mm |
BCLS II Investco | 5.38 mm | $126.99 mm |
AMGN AMGEN | 4.91 mm | $0.00 |
Morningside Venture Investments | 4.06 mm | $40.57 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Apr 24 | Juliette Berangere Audet | Option Ordinary Shares | Grant | Acquire A | No | No | 21.37 | 250,000 | 5.34 mm | 250,000 |
26 Mar 24 | Johannes Jacob Pieter Kastelein | Ordinary Shares | Sell | Dispose S | Yes | No | 21.5 | 190,476 | 4.10 mm | 0 |
26 Mar 24 | Johannes Jacob Pieter Kastelein | Ordinary Shares | Payment of exercise | Dispose F | Yes | No | 22.72 | 11,197 | 254.40 k | 190,476 |
26 Mar 24 | Johannes Jacob Pieter Kastelein | Ordinary Shares | Option exercise | Acquire M | Yes | No | 0 | 201,673 | 0.00 | 201,673 |
26 Mar 24 | Johannes Jacob Pieter Kastelein | Option Ordinary Shares | Option exercise | Dispose M | Yes | No | 0 | 201,673 | 0.00 | 970,229 |
26 Mar 24 | James N Topper | Ordinary Shares | Buy | Acquire P | Yes | No | 21.5 | 8,429 | 181.22 k | 3,008,429 |
Press releases
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
7 Jun 24
BioAge Appoints Renowned Cardiologist and Biopharma Entrepreneur Michael H. Davidson, MD, to its Board of Directors
9 Apr 24
NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease
9 Apr 24